176 related articles for article (PubMed ID: 33815322)
1. A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators.
Matsuda K; Kobayakawa T; Kariya R; Tsuchiya K; Ryu S; Tsuji K; Ishii T; Gatanaga H; Yoshimura K; Okada S; Hamada A; Mitsuya H; Tamamura H; Maeda K
Front Microbiol; 2021; 12():636276. PubMed ID: 33815322
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity.
Ishii T; Kobayakawa T; Matsuda K; Tsuji K; Ohashi N; Nakahata S; Noborio A; Yoshimura K; Mitsuya H; Maeda K; Tamamura H
Eur J Med Chem; 2023 Aug; 256():115449. PubMed ID: 37224601
[TBL] [Abstract][Full Text] [Related]
3. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents.
Ishii T; Kobayakawa T; Matsuda K; Nigorikawa K; Bolah P; Noborio A; Tsuji K; Ohashi N; Yoshimura K; Nomura W; Mitsuya H; Maeda K; Tamamura H
ACS Infect Dis; 2024 Jun; 10(6):2250-2261. PubMed ID: 38771724
[TBL] [Abstract][Full Text] [Related]
5. The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Washizaki A; Murata M; Seki Y; Kikumori M; Tang Y; Tan W; Wardani NP; Irie K; Akari H
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696466
[TBL] [Abstract][Full Text] [Related]
6. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
7. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
8. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
9. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
Rochat MA; Schlaepfer E; Speck RF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
11. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs.
Ait-Ammar A; Kula A; Darcis G; Verdikt R; De Wit S; Gautier V; Mallon PWG; Marcello A; Rohr O; Van Lint C
Front Microbiol; 2019; 10():3060. PubMed ID: 32038533
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
14. T cell toxicity of HIV latency reversing agents.
Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
[TBL] [Abstract][Full Text] [Related]
15. 4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells.
Kitamura H; Sukegawa S; Matsuda K; Tanimoto K; Kobayakawa T; Takahashi K; Tamamura H; Tsuchiya K; Gatanaga H; Maeda K; Takeuchi H
Biochem Biophys Res Commun; 2023 Jan; 641():139-147. PubMed ID: 36527748
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
[TBL] [Abstract][Full Text] [Related]
17. Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection
Hattori SI; Matsuda K; Tsuchiya K; Gatanaga H; Oka S; Yoshimura K; Mitsuya H; Maeda K
Front Microbiol; 2018; 9():2022. PubMed ID: 30283406
[TBL] [Abstract][Full Text] [Related]
18. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
[TBL] [Abstract][Full Text] [Related]
20. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
